Patents
Patents for A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy (86,964)
11/2011
11/03/2011US20110269122 Hereditary hemochromatosis gene
11/03/2011US20110268970 Mesoporous nanoparticles
11/03/2011US20110268810 Polymeric materials loaded with mutagenic and recombinagenic nucleic acids
11/03/2011US20110268724 Methods and materials relating to cd84-like polypeptides and polynucleotides
11/03/2011US20110268720 Formulations of 5-fluorocytosine and uses thereof
11/03/2011US20110268713 Variants of Ancestral Uricases and Uses Thereof
11/03/2011US20110268711 Pancreatic stellate cell specific promoter and uses thereof
11/03/2011US20110268701 Stress-responsive induction of a therapeutic agent and methods of use
11/03/2011US20110268659 High shear application in drug delivery
11/03/2011CA2800818A1 Cationic lipid
11/02/2011EP2383346A1 Method of increasing the function of an AAV vector
11/02/2011EP2383342A1 Fusion proteins of mycobacterium tuberculosis antigens and their uses
11/02/2011EP2383339A1 Gene trapping for use in gene therapy
11/02/2011EP2382997A1 Compositions and methods for inhibiting expression of anti-apoptotic genes
11/02/2011EP2382992A1 Pharmaceutical composition for treating obesity or diabetes
11/02/2011EP2382011A1 Compositions for the treatment of gluten intolerance and uses thereof
11/02/2011EP2381965A2 Modulation of pre-mrna using splice modulating oligonucleotides as therapeutic agents in the treatment of disease
11/02/2011EP2381934A2 Improving cognitive function
11/02/2011EP1461449B1 System for monitoring bacterial tumor treatment
11/02/2011EP1212359B1 Method for detecting the expression of an envelope protein of a human endogenous retrovirus and uses of a gene coding for said protein
11/02/2011EP1036180B2 Vaccine prepared with circovirus type b sequences related to piglet weight loss disease (pwd)
11/02/2011CN1629185B Fusion proteins of mycobacterium tuberculosis antigens and their uses
11/02/2011CN102231979A Processes and compositions for liposomal and efficient delivery of gene silencing therapeutics
11/02/2011CN102229962A Oncolytic adenovirus vector for modifying and expressing two exogenous genes by fibrin, construction method and application of vector
11/02/2011CN102229961A Conditionally replicating oncolytic adenoviral vector used for expressing two exogenous genes and modified by small peptide, construction method and application thereof
11/02/2011CN102229958A Human and mammal cell expression vector and application thereof
11/02/2011CN102229933A Aptamer capable of identifying hepatitis C virus (HCV) nonstructural 5A (NS5A) protein, derivatives thereof and screening method and use thereof
11/02/2011CN102229932A Nucleic acid aptamer capable of identifying HCV E1E2 (hepatitis C virus E1E2), nucleic acid aptamer derivatives and screening method and application thereof
11/02/2011CN102229928A Small-interfering RNA (Ribonucleic Acid) of human RBBP6 (Retinoblastoma-binding Proteingene) and application thereof
11/02/2011CN102229664A Recombinant melittin and application thereof
11/02/2011CN102229660A Truncated human papillomavirus 33 type L1 protein
11/02/2011CN102228698A HPV58 (Human Papilloma Virus) type therapeutic composite genetic vaccine and construction method thereof
11/02/2011CN102228697A Application of microRNA (Ribonucleic Acid)-26 in preparing medicament for preventing and treating atrial fibrillation
11/02/2011CN101642462B Tumor inhibitor NRN1SR42
11/02/2011CN101014708B Use of antisense oligonucleotides or sirna to suppress expression of eif-5a1
11/01/2011US8048995 Human skeletal muscle-specific ubiquitin-conjugating enzyme
11/01/2011US8048918 Treatment of hyperproliferative diseases
11/01/2011US8048847 Derivatives of the IL-2 receptor gamma chain, their production and use
11/01/2011US8048844 Preventing airway mucus production by administration of EGF-R antagonists
11/01/2011US8048646 NELL peptide expression systems and bone formation activity of NELL peptide
11/01/2011US8048629 Detection of extracellular tumor-associated nucleic acid in blood plasma or serum
11/01/2011US8048428 DNA composition encoding an immunogenic VEGF receptor peptide and methods of use thereof
11/01/2011US8048410 In vivo and ex vivo gene transfer into renal tissue using gutless adenovirus vectors
11/01/2011CA2402247C Biodegradable immunomodulatory formulations and methods for use thereof
11/01/2011CA2337967C Recombinant uricase protein
11/01/2011CA2320073C Method of controlling proliferation and differentiation of stem and progenitor cells
10/2011
10/27/2011WO2011133918A1 Modulation of gm3 synthase (gm3s) expression
10/27/2011WO2011133915A1 Modulation of glucosylceramide synthase (gcs) expression
10/27/2011WO2011133901A2 Aav-based treatment of cholesterol-related disorders
10/27/2011WO2011133889A2 NOVEL STRUCTURALLY DESIGNED shRNAs
10/27/2011WO2011133878A2 Compositions and methods for selectively producing sirna
10/27/2011WO2011133876A2 Oligonucleotides comprising acyclic and abasic nucleosides and analogs
10/27/2011WO2011133870A2 Vaccines comprising adenovirus vectors and signaling lymphocyte activating molecule-associated protein (sap)
10/27/2011WO2011133868A2 Conformationally restricted dinucleotide monomers and oligonucleotides
10/27/2011WO2011133802A1 Compositions and methods for treatment of lysosomal storage disorders
10/27/2011WO2011133687A2 Methods and compositions for inhibition of beta2-adrenergic receptor degradation
10/27/2011WO2011133526A1 Compositions and methods for the modification of gene transcription
10/27/2011WO2011133424A2 Genetic amplification of iqgap1 in cancer
10/27/2011WO2011133211A2 COMPOSITIONS FOR BINDING β-ARRESTIN, AND THEIR USE TO MODULATE β-ARRESTIN ACTIVITY
10/27/2011WO2011132713A1 Lipid membrane structure with nuclear transferability
10/27/2011WO2011132672A1 Method for stabilizing functional nucleic acids
10/27/2011WO2011131360A2 Method of determining the metastatic potential of a tumor
10/27/2011WO2011084455A3 Treatment of membrane bound transcription factor peptidase, site 1 (mbtps1) related diseases by inhibition of natural antisense transcript to mbtps1
10/27/2011WO2011056005A3 Novel sirna structure for minimizing off-target effects caused by antisense strands, and use thereof
10/27/2011WO2011038205A3 Treatment of growth hormone (gh) related diseases by inhibition of natural antisense transcript to gh
10/27/2011US20110265195 Unique associated kaposi's sarcoma virus sequences and uses thereof
10/27/2011US20110263831 NUCLEAR FACTOR kappaB INDUCING FACTOR
10/27/2011US20110263690 Methods and Compositions for use in Gene Therapy for Treatment of Hemophilia
10/27/2011US20110263689 AKT Ligands and Polynucleotides Encoding AKT Ligands
10/27/2011US20110263483 Compositions and methods for treating pathologic angiogenesis and vascular permeability
10/27/2011US20110263027 Adeno-associated virus (AAV) sequences and isolating novel sequences identified thereby
10/27/2011US20110262527 Cationic lipids and methods of use
10/27/2011US20110262387 Methods and materials for reducing or suppressing amyloid deposition
10/27/2011CA2833908A1 Cns targeting aav vectors and methods of use thereof
10/27/2011CA2795815A1 Novel structurally designed shrnas
10/26/2011EP2380991A1 Method of determining the metastatic potential of a tumor
10/26/2011EP2193200B1 Nucleic acid codifying for a utrophin transcription specific regulating protein, protein codified thereby and uses thereof
10/26/2011EP1427837B1 Modular transfection systems based on nucleoprotein filaments
10/26/2011EP1409748B1 Recombinant Adenoviruses comprising simian adenovirus proteins and uses thereof.
10/26/2011EP1060247B2 Ox-40 receptor binding agent for use in methods for enhancing tumour antigen-specific immune response
10/26/2011CN102227237A Host cell kinases as targets for antiviral therapies against hcv infection
10/26/2011CN102226203A Construction and application of dual shRNA expression plasmid of dual chU6 promoter
10/26/2011CN102226186A Activated Bax gene for treating malignant tumor by taking adenovirus as carrier
10/26/2011CN102226179A PRR11 gene and FAM33A gene bidirectional promoter and application thereof
10/26/2011CN102225209A Preparation method of nano magnetic granule composite system
10/25/2011US8044183 Process for the production of immunogenic compositions
10/25/2011US8043855 vector contains an adenoviral genome from which the open reading frames E1 and/or E3 have been deleted, but retains enough sequence to make it able to replicate in vitro; also contains a DNA sequence regulated by promoters that encode for fibrosis treatment proteins
10/25/2011US8043831 Therapeutic agents comprising pro-apoptotic proteins
10/25/2011US8043816 Compositions and methods for temperature-dependent nucleic acid synthesis
10/25/2011US8043801 Method of screening for agents to treat heart failure
10/25/2011US8043623 Immunogenic peptides for the treatment of prostate and breast cancer
10/25/2011US8043610 Freeze-dried composition of inactivated virus envelope with membrane fusion activity
10/25/2011CA2415923C Novel tumor antigen useful in diagnosis and therapy of bladder, ovary, lung and kidney cancers
10/25/2011CA2395499C Chlamydia antigens and corresponding dna fragments and uses thereof
10/20/2011WO2011130660A2 Sumo as a marker of cancer development and target for cancer therapy
10/20/2011WO2011130658A1 Custom designed microbubble contrast agents and techniques of ultrasound delivery optimized for nucleic acid delivery to alter gene expression
10/20/2011WO2011130491A2 Methods and compositions for treating hiv
10/20/2011WO2011130458A2 Rna aptamers against baff-r as cell-type specific delivery agents and methods for their use
10/20/2011WO2011130426A2 Compositions and methods for treatment of melanoma
10/20/2011WO2011129427A1 Diagnostic agent and therapeutic agent for cancer